These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 25248002

  • 1. eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.
    Pedersen N, Thielsen P, Martinsen L, Bennedsen M, Haaber A, Langholz E, Végh Z, Duricova D, Jess T, Bell S, Burisch J, Munkholm P.
    Inflamm Bowel Dis; 2014 Dec; 20(12):2276-85. PubMed ID: 25248002
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. EHealth: self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS.
    Pedersen N.
    Dan Med J; 2015 Dec; 62(12):B5168. PubMed ID: 26621403
    [Abstract] [Full Text] [Related]

  • 4. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis.
    Yamamoto T, Shimoyama T, Matsumoto K.
    Aliment Pharmacol Ther; 2015 Sep; 42(5):549-58. PubMed ID: 26140337
    [Abstract] [Full Text] [Related]

  • 5. Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment.
    Elkjaer M, Burisch J, Avnstrøm S, Lynge E, Munkholm P.
    Eur J Gastroenterol Hepatol; 2010 Jun; 22(6):695-704. PubMed ID: 19543101
    [Abstract] [Full Text] [Related]

  • 6. Methodological Approach to Mesalazine Treatment in Patients with Mild-to-moderate Ulcerative Colitis.
    Agilli M, Dogan T, Ergin G.
    Inflamm Bowel Dis; 2015 Aug; 21(8):E14-5. PubMed ID: 26083615
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
    Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE.
    Aliment Pharmacol Ther; 2007 Jul 15; 26(2):205-15. PubMed ID: 17593066
    [Abstract] [Full Text] [Related]

  • 9. Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study.
    Keil R, Wasserbauer M, Zádorová Z, Kojecký V, Hlava Š, Št'ovíček J, Chudý J, Roznětinská M, Drábek J, Kubišová N, Lochmannová J.
    Scand J Gastroenterol; 2018 Apr 15; 53(4):459-465. PubMed ID: 29560753
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.
    Hyams JS, Davis S, Mack DR, Boyle B, Griffiths AM, LeLeiko NS, Sauer CG, Keljo DJ, Markowitz J, Baker SS, Rosh J, Baldassano RN, Patel A, Pfefferkorn M, Otley A, Heyman M, Noe J, Oliva-Hemker M, Rufo P, Strople J, Ziring D, Guthery SL, Sudel B, Benkov K, Wali P, Moulton D, Evans J, Kappelman MD, Marquis A, Sylvester FA, Collins MH, Venkateswaran S, Dubinsky M, Tangpricha V, Spada KL, Britt A, Saul B, Gotman N, Wang J, Serrano J, Kugathasan S, Walters T, Denson LA.
    Lancet Gastroenterol Hepatol; 2017 Dec 15; 2(12):855-868. PubMed ID: 28939374
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.
    Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R.
    Gut; 2008 Jul 15; 57(7):893-902. PubMed ID: 18272546
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
    Flourié B, Hagège H, Tucat G, Maetz D, Hébuterne X, Kuyvenhoven JP, Tan TG, Pierik MJ, Masclee AA, Dewit O, Probert CS, Aoucheta D, MOTUS study investigators.
    Aliment Pharmacol Ther; 2013 Apr 15; 37(8):767-75. PubMed ID: 23451806
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The effect of third-party reporting on adoption of evidence-based mesalazine regimens in ulcerative colitis: an observational study.
    Kruis W, Leifeld L, Morgenstern J, Pfützer R, Reimers B, Ceplis-Kastner S, CARE study group.
    J Crohns Colitis; 2013 May 15; 7(4):e125-32. PubMed ID: 22951030
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.